Featured Research

from universities, journals, and other organizations

Pain medication, resiniferatoxin, may increase sepsis-related mortality

Date:
April 27, 2011
Source:
Children's National Medical Center
Summary:
Pain researchers have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

The study, which appears in the May 1 edition of the journal Anesthesiology, sheds new light on the role of a pain receptor, transient receptor potential vanilloid-1 (TRPV1), and how medications designed to impact this receptor's relay of the pain sensation to the brain might work in humans.

Scientists, led by Zenaide Quezado, MD, director of the Pain Neurobiology Laboratory of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National, studied in animal models the effects of two different medications, resiniferatoxin and capsazepine, that are known to impact TRPV1, an ion receptor channel that signals sharp, painful stimuli to the brain, and triggers a pain response. These drugs block the activation of the TRPV1 receptor in different ways. For example, resiniferatoxin binds to the TRPV1 receptor and as a result opens calcium channels and ultimately destroys the nerves that have the receptor. The team discovered that, in the case of resiniferatoxin, the chemical reaction also negatively impacts the body's reaction to bacterial infections by altering cytokine and chemokine expression, signaling molecules which are key to the natural immune response to bacteria.

Resiniferatoxin shows great promise to ease chronic pain by targeting that pain in an entirely new way. If successful, it may allow patients who suffer from long-term diseases and who cannot benefit from traditional pain management medications, respite. As a result, the National Institutes of Health are undertaking a series of clinical trials in humans to determine its effectiveness.

"Our job as pain medicine researchers is to try and uncover as much about these medications and side effects as possible so that we can monitor and treat those side effects," said Dr. Quezado, senior author of the study and a pediatric anesthesiologist. "This study alerts us to a possible side effect of resiniferatoxin that might impact when and how the drug is used. However, for many patients, the chance to finally ease long term pain caused by diseases such as cancer may outweigh a risk that the medication may impact their body's ability to heal from bacterial infection."


Story Source:

The above story is based on materials provided by Children's National Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Virginia Guptill, Xizhong Cui, Alfia Khaibullina, Jason M. Keller, Nicholas Spornick, Andrew Mannes, Michael Iadarola, Zenaide M. N. Quezado. Disruption of the Transient Receptor Potential Vanilloid 1 Can Affect Survival, Bacterial Clearance, and Cytokine Gene Expression during Murine Sepsis. Anesthesiology, 2011; 1 DOI: 10.1097/ALN.0b013e318212515b

Cite This Page:

Children's National Medical Center. "Pain medication, resiniferatoxin, may increase sepsis-related mortality." ScienceDaily. ScienceDaily, 27 April 2011. <www.sciencedaily.com/releases/2011/04/110427091945.htm>.
Children's National Medical Center. (2011, April 27). Pain medication, resiniferatoxin, may increase sepsis-related mortality. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/04/110427091945.htm
Children's National Medical Center. "Pain medication, resiniferatoxin, may increase sepsis-related mortality." ScienceDaily. www.sciencedaily.com/releases/2011/04/110427091945.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins